PAP
CLRB icon

Persistent Asset Partners’s Cellectar Biosciences CLRB Stock Holding History

Persistent Asset Partners’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$258K Buy
+92,983
New +$260K 0.08% 177

Other funds holding CLRB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $349M AUM 33.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Persistent Asset Partners's CLRB Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Cellectar Biosciences (CLRB) in Q2 2026: 92,983 shares worth $258K. The stake represents 0.08% of the portfolio and ranks #177 among its holdings.

18 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Persistent Asset Partners held 92,983 shares of Cellectar Biosciences worth $258K as of Q2 2026.
  • Cellectar Biosciences was a new Persistent Asset Partners position in Q2 2026.
  • Cellectar Biosciences made up 0.08% of Persistent Asset Partners's portfolio in Q2 2026, its #177 holding.
  • 18 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.